Amyloid immunotherapies are here, but inflammaging remains a powerful driver of neurodegenerative disease. Neuroinflammation is a rich, but thus far quite elusive, source of new drug targets. Some ...

More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...

As amyloid immunotherapy enters clinical care in more countries, providers the world over are eager for more information on how well it works, and especially how safe it is. To collect such data in ...